Long-Term Study on Gene-Modified Cell Treatments

We are evaluating the long-term health effects of gene-modified cells in participants, especially children and adolescents. This includes monitoring for serious side effects and overall growth and development.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Tecartus
Tecartus is a personalized cell therapy used to treat certain aggressive blood cancers in patients whose disease has returned or not responded to treatments.
Yescarta
Yescarta is a cancer treatment that uses a patient’s own immune cells to fight certain types of lymphoma, a blood cancer.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Axicabtagene Ciloleucel
Axicabtagene ciloleucel is a substance that uses specially modified immune cells to target and kill certain B-cell blood cancers.
Brexucabtagene Autoleucel
Brexucabtagene autoleucel uses a patient’s engineered immune cells to target and help eliminate certain B‑cell blood cancers such as lymphoma and leukemia.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Medizinische Universitaet Innsbruck
Internal Medicine V – Hematology & Oncology
Innsbruck, Austria
UZ Leuven
Hematology Department
Heverlee, Belgium
Centre Hospitalier Universitaire De Bordeaux
Hematology and Cellular Therapy Department
Canéjan, France

Sponsor: Kite Pharma Inc.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.